{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:44:28Z","timestamp":1790649868967,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.diabres.2004.10.007","type":"journal-article","created":{"date-parts":[[2004,12,30]],"date-time":"2004-12-30T12:22:15Z","timestamp":1104409335000},"page":"5-13","source":"Crossref","is-referenced-by-count":63,"title":["A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome"],"prefix":"10.1016","volume":"69","author":[{"given":"Giuseppe","family":"Derosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrigo F.G.","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gaddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro D.","family":"Ragonesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario N.","family":"Piccinni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fogari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibilla","family":"Salvadeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardina","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Fogari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.diabres.2004.10.007_bib1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0735-1097(03)00088-3","article-title":"Atherothrombosis, inflammation, and diabetes","volume":"41","author":"Biondi-Zoccai","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.diabres.2004.10.007_bib2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0895-4356(02)00611-X","article-title":"Age-related changes in risk factor effects on the incidence of thromboembolic and hemorrhagic stroke","volume":"56","author":"Abbott","year":"2003","journal-title":"J. Clin. Epidemiol."},{"issue":"10","key":"10.1016\/j.diabres.2004.10.007_bib3","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/archinte.162.10.1182","article-title":"Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology","volume":"162","author":"Tsai","year":"2002","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.diabres.2004.10.007_bib4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s11892-003-0072-3","article-title":"Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis","volume":"3","author":"Theuma","year":"2003","journal-title":"Curr. Diab. Rep."},{"issue":"6","key":"10.1016\/j.diabres.2004.10.007_bib5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s11883-002-0050-2","article-title":"Dietary glycemic load and atherothrombotic risk","volume":"4","author":"Liu","year":"2002","journal-title":"Curr. Atheroscler. Rep."},{"issue":"5A","key":"10.1016\/j.diabres.2004.10.007_bib6","doi-asserted-by":"crossref","first-page":"19G","DOI":"10.1016\/S0002-9149(02)02555-9","article-title":"Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome","volume":"90","author":"Reusch","year":"2002","journal-title":"Am. J. Cardiol."},{"issue":"11","key":"10.1016\/j.diabres.2004.10.007_bib7","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1177\/009127002762491271","article-title":"Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents","volume":"42","author":"Tsikouris","year":"2002","journal-title":"J. Clin. Pharmacol."},{"issue":"9\u201310","key":"10.1016\/j.diabres.2004.10.007_bib8","first-page":"471","article-title":"Hyperhomocysteinemia: a new risk factor for degenerative diseases","volume":"48","author":"Herrmann","year":"2002","journal-title":"Clin. Lab."},{"issue":"7","key":"10.1016\/j.diabres.2004.10.007_bib9","first-page":"428","article-title":"Thrombohaemorrhagic balance in diabetes mellitus","volume":"100","author":"Ghosh","year":"2002","journal-title":"J. Indian Med. Assoc."},{"issue":"1","key":"10.1016\/j.diabres.2004.10.007_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1365-2141.2003.04233.x","article-title":"Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus","volume":"121","author":"Calverley","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.diabres.2004.10.007_bib11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1161\/01.CIR.0000050621.67499.7D","article-title":"Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity","volume":"107","author":"Sambola","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.diabres.2004.10.007_bib12","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0149-2918(03)80130-3","article-title":"The effect of l-carnitine on plasma lipoprotein (a) levels in hypercholesterolemic patients with type 2 diabetes mellitus","volume":"25","author":"Derosa","year":"2003","journal-title":"Clin. Ther."},{"issue":"4 Pt 2","key":"10.1016\/j.diabres.2004.10.007_bib13","first-page":"44","article-title":"Beneficial effects of metformin on haemostasis and vascular function in man","volume":"29","author":"Grant","year":"2003","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.diabres.2004.10.007_bib14","doi-asserted-by":"crossref","unstructured":"National Cholesterol Education Program (NCEP) Expert Panel, Summary of the third report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol (Adult Treatment Panel III), JAMA 285 (2001) 2486-2497.","DOI":"10.1001\/jama.285.19.2486"},{"key":"10.1016\/j.diabres.2004.10.007_bib15","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Screening for diabetes (Position Statement), Diabetes Care 24 (1) (2001) S21\u2013S24.","DOI":"10.2337\/diacare.25.2007.S21"},{"key":"10.1016\/j.diabres.2004.10.007_bib16","unstructured":"American Diabetes Association, Nutrition recommendations and principles for people with diabetes mellitus (Position Statement), Diabetes Care 24 (1) (2001) S44\u2013S47."},{"key":"10.1016\/j.diabres.2004.10.007_bib17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2004.10.007_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1126\/science.635569","article-title":"The glycosylation of haemoglobin. Relevance to Diabetes Mellitus","volume":"200","author":"Bunn","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.diabres.2004.10.007_bib19","doi-asserted-by":"crossref","unstructured":"European Diabetes Policy Group, A desktop guide to type 2 diabetes mellitus, Diab Med 16 (1999) 716\u2013730.","DOI":"10.1046\/j.1464-5491.1999.00166.x"},{"key":"10.1016\/j.diabres.2004.10.007_bib20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF01225569","article-title":"Determination of total serum insulin (IRI) in insulin-treated diabetic patients","volume":"8","author":"Heding","year":"1972","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2004.10.007_bib21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/1047-2797(92)90092-5","article-title":"On the role of coagulation and fibrinolysis in atherosclerosis","volume":"2","author":"Juhan-Vague","year":"1992","journal-title":"Ann. Epidemiol."},{"key":"10.1016\/j.diabres.2004.10.007_bib22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000205234","article-title":"Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens","volume":"17","author":"Clauss","year":"1959","journal-title":"Acta Haematol."},{"issue":"2","key":"10.1016\/j.diabres.2004.10.007_bib23","first-page":"1","article-title":"Preanalytical aspects of coagulation testing","volume":"80","author":"Narayanan","year":"1995","journal-title":"Haematologica"},{"key":"10.1016\/j.diabres.2004.10.007_bib24","series-title":"Statistical Principles in Experimental Design","author":"Winer","year":"1971"},{"key":"10.1016\/j.diabres.2004.10.007_bib25","unstructured":"American Diabetes Association, American Diabetes Association: clinical practice recommendations 2002. Diabetes Care 25 (l) (2002) S1\u2013S147."},{"issue":"10","key":"10.1016\/j.diabres.2004.10.007_bib26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1046\/j.1464-5491.2001.00582.x","article-title":"Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients","volume":"18","author":"Charpentier","year":"2001","journal-title":"Diabet. Med."},{"issue":"6a","key":"10.1016\/j.diabres.2004.10.007_bib27","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1016\/S0002-9343(00)00338-7","article-title":"Combining sulfonylureas and other oral agents","volume":"108","author":"Riddle","year":"2000","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.diabres.2004.10.007_bib28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1517\/14656566.2.4.699","article-title":"Clinical review of glimepiride","volume":"2","author":"McCall","year":"2001","journal-title":"Expert Opin. Pharmacother."},{"issue":"10","key":"10.1016\/j.diabres.2004.10.007_bib29","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/00007611-200295100-00017","article-title":"Thiazolidinediones: a review of their benefits and risks","volume":"95","author":"Ovalle","year":"2002","journal-title":"South. Med. J."},{"issue":"1","key":"10.1016\/j.diabres.2004.10.007_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1464-5491.2000.00224.x","article-title":"Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients","volume":"17","author":"Wolffenbuttel","year":"2000","journal-title":"Diabet. Med."},{"issue":"8","key":"10.1016\/j.diabres.2004.10.007_bib31","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1185\/030079902125001236","article-title":"125 Study Group, An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes","volume":"18","author":"Vongthavaravat","year":"2002","journal-title":"Curr. Med. Res. Opin."},{"issue":"11","key":"10.1016\/j.diabres.2004.10.007_bib32","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.2337\/diacare.25.11.2058","article-title":"A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes","volume":"25","author":"St John Sutton","year":"2002","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2004.10.007_bib33","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1210\/jc.2002-021786","article-title":"Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes","volume":"88","author":"Pavo","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.diabres.2004.10.007_bib34","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0149-2918(02)85040-8","article-title":"Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records","volume":"24","author":"Boyle","year":"2002","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.diabres.2004.10.007_bib35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0149-2918(03)80109-1","article-title":"Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience","volume":"25","author":"Massi-Benedetti","year":"2003","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.diabres.2004.10.007_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0168-8227(02)00254-1","article-title":"Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study","volume":"61","author":"Weitgasser","year":"2003","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"3","key":"10.1016\/j.diabres.2004.10.007_bib37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/713782132","article-title":"Glitazones: clinical effects and molecular mechanisms","volume":"34","author":"Stumvoll","year":"2002","journal-title":"Ann. Med."},{"issue":"5","key":"10.1016\/j.diabres.2004.10.007_bib38","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1463-1326.2003.00276.x","article-title":"Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes","volume":"5","author":"Harte","year":"2003","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"10.1016\/j.diabres.2004.10.007_bib39","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.ahj.2003.12.006","article-title":"Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes","volume":"147","author":"Osman","year":"2004","journal-title":"Am. Heart J."},{"issue":"4","key":"10.1016\/j.diabres.2004.10.007_bib40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1055\/s-2004-817965","article-title":"Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1","volume":"112","author":"Aso","year":"2004","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"4 Pt 2","key":"10.1016\/j.diabres.2004.10.007_bib41","doi-asserted-by":"crossref","first-page":"6S44","DOI":"10.1016\/S1262-3636(03)72787-6","article-title":"Beneficial effects of metformin on haemostasis and vascular function in man","volume":"29","author":"Grant","year":"2003","journal-title":"Diabetes Metab."}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822704003468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822704003468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T02:30:12Z","timestamp":1586053812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822704003468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0168822704003468"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2004.10.007","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}